IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC)

Publication

IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC)

Reck, M
;
Liu, SV
;
Mansfield, AS
;
Mok, TSK
;
Scherpereel, A
;
Reinmuth, N
;
Garassino, MC
;
Carpeno, JD
;
Califano, Raffaele
;
Nishio, M
... show 10 more

Affiliation

Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany.

Date

2019

Collections

All Christie Publications

Show all metadata

Files

From UNPAYWALL. Conference abstract

Adobe PDF, 133.52 KB

Type

Meetings and Proceedings

Citation

Reck M, Liu SV, Mansfield AS, Mok TSK, Scherpereel A, Reinmuth N, et al. 1736OI Mpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). Annals of Oncology. 2019;30(Supplement_5):710.

URI

http://hdl.handle.net/10541/622595